← All trials
NCT05961059
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jul 27, 2023
- Last posted
- Oct 17, 2023
- Enrollment
- 85
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leiden UniversityLead sponsor
- United States ArmyCollaborator
- Leiden UniversityReponsible party - principal investigator
- University of GothenburgCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- European Vaccine Initiative (EVI), Heidelberg, GermanyCollaborator
- PATHCollaborator
- Centre for Infectious Disease Research in Zambia (CIDRZ)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.